文献速递胸部病理细胞病理与分子病理

非小细胞肺癌微创活检诊断的经济价值与临床角色

Economic value and clinical role of minimally invasive, biopsy-based diagnostics in non-small cell lung cancer.
PubMed 文献 · Cancer Cytopathol · 2026-01-01

该研究比较非小细胞肺癌诊断路径中细针穿刺(FNA)与粗针活检(CNB)的经济成本,采用微成本框架和决策树模型应用于瑞典标准化癌症护理路径。结果显示,FNA优先结合快速现场评估(ROSE)使每例患者诊断成本降低约33%(7748 vs 11637瑞典克朗),且在并发症率和充分性变动下结果稳健。结论支持在具备ROSE条件下采用FNA优先策略,并预设同次CNB升级。

要点

  • 现代细胞学流程联合ROSE的非诊断采样率≤6%。
  • FNA优先路径较CNB降低每例诊断成本约33%。
  • FNA并发症更少且便于重复采样。

核心结论

  • 在具备ROSE的条件下,FNA优先策略可降低诊断成本且不损害分子检测产出。

研究设计与样本

  • 研究综合细胞学与组织活检的诊断充分性、并发症率和分子性能证据,采用微成本框架分解诊断总成本,并应用决策树模型和敏感性分析于瑞典NSCLC标准化癌症护理路径。

主要发现

  • 现代细胞学联合ROSE的非诊断采样率≤6%,支持PD-L1和广谱NGS且与手术标本突变一致性高。
  • 与CNB相比,FNA重大并发症更少并便于重复采样。
  • 瑞典示例中FNA优先路径使每例患者预期诊断成本降低约33%(7748 vs 11637瑞典克朗)。
  • 结果对并发症率±50%和充分性±5%-10%的变动稳健。

关键数值与推荐

  • FNA优先路径结合ROSE,并编码化同次CNB升级策略。

临床怎么用

  • 在具备ROSE的中心可优先采用FNA联合CNB升级策略以兼顾安全、成本和时效。
  • 绝对成本值需本地重新校准,并鼓励多中心校准以验证普适性。

局限性

  • 绝对成本值需本地重新校准。
  • 需多中心校准以确立在不同环境下的普适性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Precision oncology requires diagnostic sampling that delivers molecularly actionable material quickly and safely. In non-small cell lung cancer (NSCLC), core-needle biopsy (CNB) remains common. Yet fine-needle aspiration (FNA) has re-emerged with rapid on-site evaluation (ROSE), optimized cell blocks, and next-generation sequencing. The objective of this study was to compare the economic costs of FNA versus CNB with respect to an FNA-first with predefined CNB escalation strategy for NSCLC clinical pathways. METHOD: The authors synthesized evidence on diagnostic adequacy, complication rates, and molecular performance of cytology versus core tissue. A microcosting framework decomposed total diagnostic episode costs into sampling, processing, complications, and remedial procedures. This framework was applied to Sweden's Standardized Cancer Care Pathway for NSCLC using decision-tree modeling and sensitivity analyses. RESULTS: Modern cytology workflows with ROSE achieve a nondiagnostic sampling rate ≤6% and support programmed death-ligand 1 and broad next-generation sequencing with high mutation concordance to surgical specimens. Compared with CNB, FNA incurs fewer major complications and facilitates repeat sampling. In the Swedish illustration, an FNA-first pathway with ROSE reduced expected per-patient diagnostic cost by approximately 33% (7748 vs. 11,637 Swedish krona). The results were robust to ±50% variation in complication rates and ±5%-10% variation in adequacy. CONCLUSIONS: Reframing adequacy around molecular fitness and time to actionability supports FNA where ROSE exists, with codified, same-episode CNB escalation. This approach advances safety, capacity, and timeliness without compromising molecular yield. The authors provide a transferable cost-consequence model and implementation checklist for health systems. Local recalibration is required for absolute cost values, and multisite calibration is encouraged to establish generalizability across the different settings.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Guo J, Franzén B, Lewensohn R, et al. Economic value and clinical role of minimally invasive, biopsy-based diagnostics in non-small cell lung cancer. Cancer Cytopathol. 2026. PMID: 42708823. doi:10.1002/cncy.70152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。